These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23315207)

  • 1. Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.
    Rossi G; Bertani C; Mari S; Marini C; Renzoni G; Ogilvie G; Magi GE
    Vet Res Commun; 2013 Jun; 37(2):101-8. PubMed ID: 23315207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
    Yamada O; Kobayashi M; Sugisaki O; Ishii N; Ito K; Kuroki S; Sasaki Y; Isotani M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2011 Jul; 142(1-2):101-6. PubMed ID: 21561667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
    Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M
    Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11.
    Nakano Y; Kobayashi T; Oshima F; Fukazawa E; Yamagami T; Shiraishi Y; Takanosu M
    J Vet Med Sci; 2014 Apr; 76(4):545-8. PubMed ID: 24292246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
    J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
    Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
    Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
    Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
    Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
    Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.
    Kobayashi M; Sugisaki O; Ishii N; Yamada O; Ito K; Kuroki S; Sasaki Y; Ono K; Washizu T; Bonkobara M
    Vet J; 2012 Jul; 193(1):264-7. PubMed ID: 22153896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
    Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
    Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
    Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of proto-oncogene C-kit and correlation with morphological evaluations in canine cutaneous mast cell tumors.
    Passantino L; Passantino G; Cianciotta A; Ribaud MR; Lo Presti G; Ranieri G; Perillo A
    Immunopharmacol Immunotoxicol; 2008; 30(3):609-21. PubMed ID: 18608529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
    Ohmori K; Kawarai S; Yasuda N; Tanaka A; Matsuda H; Nishimura R; Sasaki N; Tsujimoto H; Masuda K
    Vet Immunol Immunopathol; 2008 Nov; 126(1-2):43-53. PubMed ID: 18687474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
    Verstovsek S; Akin C; Manshouri T; Quintás-Cardama A; Huynh L; Manley P; Tefferi A; Cortes J; Giles FJ; Kantarjian H
    Leuk Res; 2006 Nov; 30(11):1365-70. PubMed ID: 16797704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
    Lin TY; Bear M; Du Z; Foley KP; Ying W; Barsoum J; London C
    Exp Hematol; 2008 Oct; 36(10):1266-77. PubMed ID: 18657349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
    Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
    Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.
    Juurikivi A; Sandler C; Lindstedt KA; Kovanen PT; Juutilainen T; Leskinen MJ; Mäki T; Eklund KK
    Ann Rheum Dis; 2005 Aug; 64(8):1126-31. PubMed ID: 16014680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers.
    Gil da Costa RM; Matos E; Rema A; Lopes C; Pires MA; Gärtner F
    BMC Vet Res; 2007 Aug; 3():19. PubMed ID: 17711582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin lesions and mast cells.
    Blood; 2008 Jul; 112(1):28. PubMed ID: 18584778
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.